Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
168 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape. Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 13, 6, 9 and 2 respectively.Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD). Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10 Therapeutics Development 11 Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 11 Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis 12 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 13 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 19 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 21 AnGes MG, Inc. 21 AstraZeneca Plc 22 Athera Biotechnologies AB 23 Athersys, Inc. 24 Bayer AG 25 Betagenon AB 26 BiogenCell Ltd. 27 CardioVascular BioTherapeutics, Inc. 28 Celgene Corporation 29 Diffusion Pharmaceuticals Inc 30 Hemostemix Ltd 31 ID Pharma Co., Ltd. 32 Juventas Therapeutics, Inc. 33 LipimetiX Development Inc 34 miRagen Therapeutics, Inc. 35 Nuo Therapeutics, Inc. 36 Proteon Therapeutics, Inc. 37 Recardio GmbH 38 Resverlogix Corp. 39 Sigma-Tau S.p.A. 40 Stemedica Cell Technologies, Inc. 41 Symic Biomedical, Inc. 42 Theravasc, Inc. 43 VESSL Therapeutics Ltd 44 ViroMed Co Ltd 45 Yuyu Pharma, Inc. 46 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 ACP-01 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 AEM-28 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 ALD-301 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 alprostadil - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Annexin A-5 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 apabetalone - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 BAY-1193397 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 BC-1 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 beperminogene perplasmid - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 CVBT-141C - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 DVC-10101 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 ELS-140 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 JVS-100 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 levocarnitine propionate hydrochloride - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 MGN-6114 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 MultiGeneAngio - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 O-304 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 PC-mAb - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 PDA-002 - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 PF-05285401 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 REC-03 - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 Rejuveinix - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 rivaroxaban - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 SB-030 - Drug Profile 124 Product Description 124 Mechanism Of Action 124 R&D Progress 124 sodium nitrite SR - Drug Profile 126 Product Description 126 Mechanism Of Action 126 R&D Progress 126 Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 128 Product Description 128 Mechanism Of Action 128 R&D Progress 128 transcrocetinate sodium - Drug Profile 134 Product Description 134 Mechanism Of Action 134 R&D Progress 134 TXA-127 - Drug Profile 138 Product Description 138 Mechanism Of Action 138 R&D Progress 138 V-10 - Drug Profile 141 Product Description 141 Mechanism Of Action 141 R&D Progress 141 VM-202 - Drug Profile 142 Product Description 142 Mechanism Of Action 142 R&D Progress 142 vonapanitase - Drug Profile 145 Product Description 145 Mechanism Of Action 145 R&D Progress 145 YY-984 - Drug Profile 149 Product Description 149 Mechanism Of Action 149 R&D Progress 149 zibotentan - Drug Profile 150 Product Description 150 Mechanism Of Action 150 R&D Progress 150 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 152 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 156 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 157 Featured News & Press Releases 157 Oct 25, 2016: Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference 157 Oct 20, 2016: Dr. Jackie R. See M.D. Joins AngioSoma, Scientific Advisory Board 157 Oct 20, 2016: Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors 158 Oct 11, 2016: AngioSoma Files 3 New Patent Applications on Liprostin 158 Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada 159 Sep 29, 2016: Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients 159 Sep 28, 2016: Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS 160 Aug 11, 2016: Athera Biotechnologies completes First-in-Patient Study with New Antibody Against Immunovascular Disease 160 May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 161 Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease 162 Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease 162 Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 163 Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease 164 Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 165 Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 165 Appendix 167 Methodology 167 Coverage 167 Secondary Research 167 Primary Research 167 Expert Panel Validation 167 Contact Us 167 Disclaimer 168
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2016 11 Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Number of Products under Development by Companies, H2 2016 (Contd..1) 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Comparative Analysis by Unknown Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG, Inc., H2 2016 21 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H2 2016 22 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athera Biotechnologies AB, H2 2016 23 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H2 2016 24 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H2 2016 25 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H2 2016 26 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by BiogenCell Ltd., H2 2016 27 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2016 28 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H2 2016 29 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 30 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Ltd, H2 2016 31 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co., Ltd., H2 2016 32 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics, Inc., H2 2016 33 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by LipimetiX Development Inc, H2 2016 34 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H2 2016 35 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics, Inc., H2 2016 36 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H2 2016 37 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H2 2016 38 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp., H2 2016 39 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau S.p.A., H2 2016 40 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 41 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Symic Biomedical, Inc., H2 2016 42 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H2 2016 43 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by VESSL Therapeutics Ltd, H2 2016 44 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co Ltd, H2 2016 45 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma, Inc., H2 2016 46 Assessment by Monotherapy Products, H2 2016 47 Number of Products by Stage and Target, H2 2016 49 Number of Products by Stage and Mechanism of Action, H2 2016 51 Number of Products by Stage and Route of Administration, H2 2016 53 Number of Products by Stage and Molecule Type, H2 2016 55 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H2 2016 152 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H2 2016 153 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..2), H2 2016 154 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..3), H2 2016 155 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H2 2016 156
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
